Medtronic reports positive data from cryoballoon catheter ablation study

Medical Company Product News

Medtronic has announced the findings of a new study that demonstrates the benefits of cryoballoon catheter ablation in terms of cost-effectiveness.

Health economic analysis data from the FIRE AND ICE trial showed that cryoballoon catheter ablation generally performs better than radiofrequency ablation in terms of cost savings, as a result of fewer cardiovascular rehospitalisations and repeat ablations.

“Medtronic has announced clinical trial data that demonstrates the cost-effectiveness benefits cryoballoon catheter ablation can offer over radiofrequency ablation in treating heart problems.“

Medtronic's Arctic Front cryoballoon catheter family was shown to reduce payer costs across multiple healthcare systems, compared to an established brand of radiofrequency ablation catheters. This was reflected when considering the UK, US and German systems of healthcare provision.

FIRE AND ICE was the largest multicentre prospective randomised study conducted to date comparing cryoballoon ablation and point-by-point radiofrequency ablation for the treatment of paroxysmal atrial fibrillation.

Colleen Fowler, vice-president and general manager of Medtronic's atrial fibrillation solutions business, said: "Today's findings further underscore the ability of the cryoballoon to make a difference in care across patients, physicians and healthcare systems."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news